PerkinElmer, Inc. announced that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ... more
PerkinElmer to acquire EUROIMMUN for approximately $1.3 Billion
PerkinElmer, Inc. announced that it has entered into a definitive agreement to acquireEUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN. The total purchase price of the transaction based on all outstanding shares being acquired will be approximately $1.3 billion in cash.
Based in Lübeck, Germany, with approximately 2,400 employees, EUROIMMUN is widely recognized as a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing. The company has extensive expertise and capabilities across immunology, cell biology, histology, biochemistry and molecular biology. EUROIMMUN is expected to generate approximately $310 million in revenue this year, and over the last five years, the company has averaged revenue growth of 19%. In 2016, the company generated sales in more than 130 countries worldwide, with approximately 45% of revenues in China, 30% in Europe, Middle East & Africa, 5% in the Americas and 20% in Rest of World.
The acquisition combines two innovative, results-driven cultures with a shared mission of improving global health. The combination expands PerkinElmer's reach into autoimmune and allergy diagnostic markets, while offering new infectious disease capabilities to customers in China. In addition, as a market leader in the U.S. for reproductive health, PerkinElmer will have the opportunity to drive EUROIMMUN's solutions into this well established channel.
"With the acquisition of EUROIMMUN and its talented team of professionals, we are able to leverage our combined advanced detection, imaging and assay development capabilities, along with our strong collective market positions and synergistic commercial activities, to deliver better and more complete solutions to our customers around the world," said Robert Friel, chairman and chief executive officer of PerkinElmer. "We look forward to working with the EUROIMMUN team as we partner together to help improve global health through advanced diagnostics."
"I am delighted to entrust EUROIMMUN to PerkinElmer, a company I believe shares our important mission and will secure the continuity of our culture and tradition of innovation that we have developed over the last thirty years," said Professor Winfried Stöcker, founder and chief executive officer of EUROIMMUN.
PerkinElmer's comprehensive global diagnostics portfolio will now include solutions focused on: reproductive health; autoimmune, infectious disease and allergy testing; gene analyses; and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings.
The transaction is subject to customary closing conditions and is currently anticipated to close in the fourth quarter of 2017 following the receipt of required standard regulatory approvals. The acquisition is expected to be accretive to PerkinElmer's 2018 non-GAAP earnings per share results by approximately $0.28 to $0.30. Additionally, PerkinElmer is reaffirming its 2017 revenue and earnings per share guidance.
- laboratory diagnostics
- assay development
PerkinElmer, Inc. announced that after a career of more than 20 years at the Company, including the last 12 years as chief executive officer, Robert F. Friel, has decided to retire as chairman and CEO and member of the board of directors as of the end of the Company’s fiscal year on Decembe ... more
PerkinElmer announced that its board of directors has named Prahlad Singh president and chief operating officer, effective January 1, 2019. In his expanded position, Dr. Singh will have responsibility for both the Discovery and Analytical Solutions (DAS) and Diagnostics operating divisions ... more
- 1A new, highly sensitive chemical sensor uses protein nanowires
- 2New COVID-19 test quickly and accurately detects viral RNA
- 3Diagnostic biosensor quickly detects SARS-CoV-2 from nasopharyngeal swabs
- 4Researcher Develops One Minute Coronavirus Test
- 5The Higgs boson and superconductivity
- 6A new biosensor for the COVID-19 virus
- 7How cells recognize uninvited guests
- 8A Glimpse into Real-Time Methanol Synthesis
- 9Single-cell RNA seq method developed to accurately quantify cell-specific drug effects in pancreatic islets
- 10Real-time observation of enzymatic processes on DNA
- Microbes on microscope eyepieces: could mean one in the eye for users!
- Gene editing: Taming CRISPR’s collateral damage
- Start-up Raises 16.3 million Euros to Prepare Market Launch of its SARS-CoV-2 Rapid Testing System
- Alexandra Knauer awarded as a female entrepreneur role model
- The Higgs boson and superconductivity